Cardiovascular Disease and Type 2 Diabetes:
Defining the Therapeutic Crossroads

John Venditto, MD

Explore the relationships between type 2 diabetes and cardiovascular disease (CVD) with CVD risk factors. The presenter will discuss definitions of primary and secondary prevention of CVD, including long-term oral anti-platelet trials in secondary prevention in T2D. You'll come away with an understanding of lipid and triglyceride management.

Wednesday, July 22, 2020 at 1:00 pm EST

Type 2 Diabetes and Kidney Disease: Patient engagement and how to manage chronic conditions

Robert M. Perkins, MD, MPH and Ted Okerson, MD, FACP, FACE, FTOS

Understand key points of clinical intervention, as well as how to engage patients in discussions about chronic conditions early in development of disease, and how to encourage adopting healthy behaviors.

Wednesday, October 21, 2020 at 1:00 pm EST

Relationship of Type 2 Diabetes and Diabetic Kidney Disease: Progression of these chronic conditions

Speaker TBA

This webinar will give you an understanding of how type 2 diabetes and diabetic kidney disease (DKD) are related. Understand the continuum of disease progression and key points of intervention, as well as the treatment options when treating complications of DKD.

Wednesday, September 23, 2020 at 1:00 pm EST

SGLT-2 Inhibitor Overview and Emphasis
on Cardio-Renal Axis

Speaker TBA

This webinar will go over how SGLT-2 inhibition impacts the physiology of the kidney and heart. Understand the clinical effects on glycemia, MACE, hHF, and renal endpoints in diabetes, as well as the evolving landscape and use of these agents in patients without diabetes.

Wednesday, December 2, 2020 at 1:00 pm EST

Heart Failure Associated with Type 2 Diabetes

Originally presented on May 27, 2020 by John Venditto, MD, MBA, FACC and Curtis Triplitt, PharmD, CDCES

This webinar provides a basic overview of diabetic / non-diabetic cardiomyopathy and clinical perspectives on heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). Participants will be able to outline the link between diabetes and heart failure as well as understand treatment options for heart failure (HF) in patients with diabetes.

Upon completion of this activity, participants will be able to:

1. Define the link between T2D and HF
2. Review clinical perspectives on HFpEF and HFrEF
3. Understand treatment options for HF in patients with and without type 2 diabetes

2020 Guideline Updates and Implications to Patient Care

Originally presented on June 24, 2020 by Ted Okerson, MD, FACP, FACE, FTOS, Paul Tomasic, MD, Davida F. Kruger, MSN, APN-BC, BC-ADM, and Curtis Triplitt, PharmD, CDCES

In this panel discussion webinar, we'll review and discuss changes to the ADA/EASD treatment guidelines and the importance of treating cardiovascular disease (CVD) and diabetic kidney disease (DKD), as well as the impact of treatments on glycemia and weight. The presenters will facilitate a discussion on this impact to providers and their patients.

Upon completion of this activity, participants will be able to:

1. Understand changes to the ADA/EASD treatment guidelines and importance of treating CVD and DKD
2. Understand impact of treatments on glycemia and weight
3. Discussion on impact to providers and patients